Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

Older adults and women using Wegovy for obesity management may be more likely to lose lean mass, although increasing protein intake may help protect against lean mass loss, according to a speaker.

The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and obesi | ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Wegovy launched here is to support Singapore’s efforts in improving population health: Novo Nordisk Read more at straitstimes ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

By Rishika Sadam HYDERABAD (Reuters) -Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in ...

So Wegovy’s approval by the FDA may open up a whole new avenue of possible approaches to managing obesity and overweight conditions. Other GLP-1-like treatments are already under development.